-
公开(公告)号：US20210015918A1
公开(公告)日：2021-01-21
申请号：US17033141
申请日：2020-09-25
Applicant: Genentech, Inc.
Inventor： Gwendolyn FYFE , Eric HOLMGREN , Robert D. MASS , William NOVOTNY
IPC: A61K39/395 , A61K45/06 , A61K31/522 , A61K38/50 , A61K31/525 , A61K31/573 , A61K38/09 , A61K38/21 , C07K16/22 , A61K31/282 , A61K31/4545 , A61K31/513 , A61K31/519 , A61K31/337 , A61K31/4745 , A61K31/7068 , A61K9/00 , A61K31/555 , C07K16/30
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
-
公开(公告)号：US20200171148A1
公开(公告)日：2020-06-04
申请号：US16781281
申请日：2020-02-04
Applicant: Genentech, Inc.
Inventor： Gwendolyn FYFE , Eric HOLMGREN , Robert D. MASS , William NOVOTNY
IPC: A61K39/395 , A61K38/21 , A61K38/09 , A61K31/573 , A61K31/525 , A61K38/50 , A61K31/522 , C07K16/30 , A61K31/555 , A61K9/00 , A61K31/7068 , A61K31/4745 , A61K31/337 , A61K31/519 , A61K31/513 , A61K31/4545 , A61K31/282 , C07K16/22 , A61K45/06
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
-
公开(公告)号：US20160304594A1
公开(公告)日：2016-10-20
申请号：US15080897
申请日：2016-03-25
Applicant: Genentech, Inc.
Inventor： Gwendolyn FYFE , Eric HOLMGREN , Robert D. MASS , William NOVOTNY
IPC: C07K16/22 , A61K45/06 , A61K31/513 , C07K16/30 , A61K31/4745 , A61K31/555 , A61K9/00 , A61K39/395 , A61K31/519
CPC classification number: A61K39/3955 , A61K9/0019 , A61K31/282 , A61K31/337 , A61K31/4545 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/522 , A61K31/525 , A61K31/555 , A61K31/573 , A61K31/7068 , A61K38/09 , A61K38/212 , A61K38/50 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/3046 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/76 , A61K2300/00
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
-
公开(公告)号：US20150359881A1
公开(公告)日：2015-12-17
申请号：US14597754
申请日：2015-01-15
Applicant: GENENTECH, INC.
Inventor： Gwendolyn FYFE , Eric HOLMGREN , Robert D. MASS , William NOVOTNY
IPC: A61K39/395 , A61K31/519 , A61K45/06 , A61K31/282 , A61K31/7068 , A61K31/337 , A61K31/513 , A61K31/4745
CPC classification number: A61K39/3955 , A61K9/0019 , A61K31/282 , A61K31/337 , A61K31/4545 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/522 , A61K31/525 , A61K31/555 , A61K31/573 , A61K31/7068 , A61K38/09 , A61K38/212 , A61K38/50 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/3046 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/76 , A61K2300/00
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
-
公开(公告)号：US20180221473A1
公开(公告)日：2018-08-09
申请号：US15705006
申请日：2017-09-14
Applicant: Genentech, Inc.
Inventor： Gwendolyn FYFE , Eric HOLMGREN , Robert D. MASS , William NOVOTNY
IPC: A61K39/395 , A61K45/06 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , C07K16/30 , C07K16/22 , A61K9/00 , A61K31/7068 , A61K31/555 , A61K39/00
CPC classification number: A61K39/3955 , A61K9/0019 , A61K31/282 , A61K31/337 , A61K31/4545 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/522 , A61K31/525 , A61K31/555 , A61K31/573 , A61K31/7068 , A61K38/09 , A61K38/212 , A61K38/50 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/3046 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/76 , A61K2300/00
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
-
Patent Agency Ranking
6.发明申请VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS 审中-公开VEGF特异性拮抗剂用于治疗和治疗早期治疗和早期阶段肿瘤公开(公告)号：US20160108116A1
公开(公告)日：2016-04-21
申请号：US14752284
申请日：2015-06-26
Applicant: GENENTECH, INC.
Inventor： Napoleone FERRARA , Nina KORSISAARI , Robert D. MASS
IPC: C07K16/22 , C07K16/30 , A61K45/06 , A61K39/395
CPC classification number: C07K16/22 , A61K38/179 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/24 , C07K2317/73 , A61K2300/00
Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
Abstract translation: 本文公开了使用抗VEGF特异性拮抗剂治疗良性，癌前或非转移性肿瘤的方法。 还公开了使用抗VEGF特异性拮抗剂治疗患有发展良性，癌前或非转移性肿瘤的风险的受试者的方法。 还公开了使用抗VEGF特异性拮抗剂治疗或预防肿瘤复发以及在新辅助和辅助癌症治疗中使用VEGF特异性拮抗剂的方法。
-
公开(公告)号：US20230218755A1
公开(公告)日：2023-07-13
申请号：US18183467
申请日：2023-03-14
Applicant: Genentech, Inc.
Inventor： Gwendolyn FYFE , Eric HOLMGREN , Robert D. MASS , William NOVOTNY
IPC: A61K39/395 , C07K16/22 , A61K31/525 , A61K31/519 , C07K16/30 , A61K31/4545 , A61K9/00 , A61K38/50 , A61K31/337 , A61K31/282 , A61K38/09 , A61K31/555 , A61K31/522 , A61K31/573 , A61K38/21 , A61K31/513 , A61K31/7068 , A61K31/4745 , A61K45/06 , A61K39/00
CPC classification number: A61K39/3955 , C07K16/22 , A61K31/525 , A61K31/519 , C07K16/3046 , A61K31/4545 , A61K9/0019 , A61K39/39541 , A61K38/50 , A61K31/337 , A61K31/282 , A61K38/09 , A61K31/555 , A61K31/522 , A61K31/573 , A61K38/212 , A61K31/513 , A61K31/7068 , A61K39/39558 , A61K31/4745 , A61K45/06 , A61K2039/505 , C07K2317/567 , C07K2317/565 , C07K2317/24 , C07K2317/76 , C07K2317/21
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
-
公开(公告)号：US20190307881A1
公开(公告)日：2019-10-10
申请号：US16452144
申请日：2019-06-25
Applicant: Genentech, Inc.
Inventor： Gwendolyn FYFE , Eric HOLMGREN , Robert D. MASS , William NOVOTNY
IPC: A61K39/395 , A61K31/555 , A61K31/513 , A61K31/282 , A61K45/06 , A61K31/4745 , A61K31/4545 , C07K16/22 , C07K16/30 , A61K9/00 , A61K31/519 , A61K31/7068 , A61K31/337
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
-
9.发明申请公开(公告)号：US20180208647A1
公开(公告)日：2018-07-26
申请号：US15677804
申请日：2017-08-15
Applicant: Genentech, Inc.
Inventor： Napoleone FERRARA , Nina KORSISAARI , Robert D. MASS
CPC classification number: C07K16/22 , A61K38/179 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/24 , C07K2317/73 , A61K2300/00
Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
-
10.发明申请GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY 审中-公开用于改善对ErbB拮抗剂治疗有效应答的基因检测测定公开(公告)号：US20150150970A1
公开(公告)日：2015-06-04
申请号：US14611712
申请日：2015-02-02
Applicant: GENENTECH, INC.
Inventor： Robert D. MASS
IPC: A61K39/395 , A61K31/337 , C12Q1/68 , C07K16/40 , C07K16/28
CPC classification number: A61K39/39558 , A61K31/337 , A61K38/00 , C07K16/2863 , C07K16/32 , C07K16/40 , C07K2317/24 , C12Q1/6841 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/5023 , G01N33/57415 , A61K31/335 , A61K2300/00 , C12Q2537/157
Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
Abstract translation: 本发明提供了一种通过基因扩增测定法与EGFR拮抗剂更有效地治疗对过表达EGFR的肿瘤敏感或诊断的患者的方法。 这样的方法包括向已经发现其肿瘤细胞erbB1基因被扩增的受试者施用癌症治疗剂量的EGFR拮抗剂，优选除了化学治疗剂之外，例如通过荧光原位杂交。 所述EGFR拮抗剂包括抗EGFR抗体。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.021 seconds)
